Compare LOVE & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOVE | FULC |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.4M | 285.4M |
| IPO Year | 2018 | 2019 |
| Metric | LOVE | FULC |
|---|---|---|
| Price | $14.36 | $3.71 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 5 |
| Target Price | ★ $23.17 | $3.67 |
| AVG Volume (30 Days) | 198.0K | ★ 1.3M |
| Earning Date | 09-10-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $697,115,000.00 | N/A |
| Revenue This Year | $0.13 | N/A |
| Revenue Next Year | $7.96 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.42 | N/A |
| 52 Week Low | $10.33 | $2.83 |
| 52 Week High | $19.25 | $15.74 |
| Indicator | LOVE | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 44.98 | 46.26 |
| Support Level | $13.43 | $3.62 |
| Resistance Level | $16.13 | $3.91 |
| Average True Range (ATR) | 0.58 | 0.06 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 19.43 | 44.83 |
The Lovesac Co designs, manufactures and sells alternative furniture which is comprised of modular couches called sactionals and premium foam beanbag chairs called sacs. It also offers other accessories such as sactional-specific drink holders, Footsac blankets, decorative pillows, fitted seat tables, and ottomans. Its products are sold across the United States through its website or company-owned retail stores which are used in homes and offices. The majority of the firm's revenue is derived from the sale of Sactionals.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.